Company intelligence / Profile preview

Site Impact

Ness Ziona, Central District, Israelsiteimpact.com ↗

Ownership: Private
Development stage: Other

Overview

Padeliporfin VTP is being evaluated in a pivotal Phase 3 trial ("ENLIGHTED") for low-grade UTUC. Interim analysis at ASCO 2025 showed that, among response-evaluable patients, 73% achieved complete response and 13.5% partial response at the end of initial treatment phase. The platform is also being explored in high-grade UTUC, PDAC, and NSCLC.

Therapeutic areas: Oncology
Modalities: Small moleculeDevice (drug-device combination)Photosensitizer-based therapy
Industry: Biotech

Partnerships

Weizmann Institute of ScienceMemorial Sloan Kettering Cancer Center

Beyond the preview

Go deeper on Site Impact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Site Impact.

Explore the full profile